Abstract
Respiratory bacterial pathogens are a leading cause of infectious death globally, a crisis exacerbated by the rise of multi-antibiotic resistant strains. This study presents an integrative analysis of human gene expression data from challenges with Pseudomonas aeruginosa (Gram-negative) and Streptococcus pneumoniae (Gram-positive). By applying a differential gene and pathway enrichment pipeline to publicly available GEO datasets, researchers identified 72 canonical human pathways common to both pathogens. While many are linked to immune response, the analysis revealed novel interactions, such as the SUMO1 pathway, as potential players in bacterial infection. Furthermore, 36 of these pathways overlap with previous findings on respiratory viruses, suggesting a core host response. These results highlight several drug-repurposing opportunities to treat infections by modulating host targets.
Addressing the Crisis of Antibiotic Resistance
Respiratory infections remain a top global health concern. The emergence of "ESKAPE" pathogens like P. aeruginosa and resistant S. pneumoniae strains has rendered many traditional antibiotics increasingly ineffective. This research advocates for Host-Directed Therapy—targeting the host cellular pathways that bacteria hijack to survive, rather than the bacteria themselves. This approach could potentially bypass the rapid evolution of drug resistance.
Methodology: A Bioinformatics Pipeline
The researchers developed a multi-stage pipeline to harmonize disparate datasets and extract meaningful biological signals from the noise of individual studies.
- Data Mining & Filtering: Querying the NCBI Gene Expression Omnibus (GEO) for human mRNA datasets involving major respiratory pathogens, narrowing the scope to high-quality studies of P. aeruginosa and S. pneumoniae.
- Quality Control: Applying statistical tests including MAD score, PCA, and kernel density to ensure sample comparability.
- Differential Expression & Pathway Mapping: Identifying genes with a fold-change > 1.5 and mapping them to 683 canonical pathways in the MetaBase database.
- Comparative Analysis: Cross-referencing bacterial response pathways with viral data to identify universal "pan-infection" signatures.
Datasets and Scope
From an initial pool of 18 datasets, four high-quality datasets (GSE1469, GSE6269, GSE6802, and GSE8527) were selected for the final analysis. These represented various human cell environments, including lung epithelial cells (A549, BEAS-2B), pharyngeal cells (Detroit 562), and peripheral blood mononuclear cells (PBMC).
Key Insights: The SUMO1 Hub and Viral Overlap
A standout discovery was the significant enrichment of the SUMO1 pathway. SUMOylation, a post-translational modification similar to ubiquitination, regulates protein stability and localization. While its role is established in viral infections, this study identifies it as a critical regulatory hub that bacteria likely exploit to dampen host immune defenses.
Additionally, the study found that 36 pathways are shared between bacterial and viral respiratory infections. This overlap (p-value $4.0 \times 10^{-18}$) suggests a generalized "respiratory distress" signature in human cells, regardless of whether the invader is a virus or a bacterium.
Results and Therapeutic Potential
- 72 Shared Pathways: A robust set of pathways was identified across both Gram-positive and Gram-negative challenges.
- 69 Core Genes: Consistently differentially expressed genes were found across species.
- Drug Repurposing: The analysis identified 11 genes associated with approved drugs. For instance, Integrin Antagonists (e.g., Abciximab) might block bacterial adhesion, while anti-inflammatories targeting PTGS2 (COX-2) or IL1B could mitigate the severe "cytokine storm" seen in pneumonia.
Limitations and Future Directions
While promising, the study is limited by a small final sample size and a reliance on in vitro cell line data, which lacks the systemic complexity of a living host. These findings serve as high-confidence hypotheses that require validation through preclinical and clinical trials. Future work will focus on expanding the meta-analysis to broader pathogen sets and investigating the SUMO1 pathway as a viable therapeutic target.
Summary updated